This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Estimates Rising for Moderna (MRNA): Will It Gain?
by Zacks Equity Research
Moderna (MRNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study
by Zacks Equity Research
Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.
Company News for Apr 7, 2021
by Zacks Equity Research
Companies in The News Are: ILMN, NVAX, MRNA, BP.
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine
by Zacks Equity Research
Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.
5 Stocks With High Earnings Yield for Superior Returns
by Rimmi Singhi
Check out high earnings yield stocks including AA, USAK, GIII, MU and MRNA for a standout portfolio.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies
by Zacks Equity Research
Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $132.55, moving +1.22% from the previous trading session.
The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna
Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Top Research Reports for Comcast, Netflix & PepsiCo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Netflix,Inc. (NFLX) and PepsiCo, Inc. (PEP).
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.
Bull of the Day: Owens and Minor (OMI)
by David Borun
This medical logistics company made big gains in 2020 - and is poised to keep heading higher.
Why Is Moderna (MRNA) Down 10.2% Since Last Earnings Report?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers (BMY) Announces Results From Opdivo Combo Study
by Zacks Equity Research
Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.
AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine
by Zacks Equity Research
AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $133.33 in the latest trading session, marking a +1.31% move from the prior day.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH
by Zacks Equity Research
NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.
Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?
by Kinjel Shah
Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.
5 S&P 500 Stocks That Zoomed 200% Plus From Pandemic Lows
by Sweta Killa
After touching a low of 2,191 on Mar 23, 2020, the S&P 500 staged a strong comeback and is on track to hit a new milestone of 4,000.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $143.74, moving +1.61% from the previous trading session.